May 2024 SOCRA Source Journal - Journal - Page 54
References (continued
Rodríguez-Pinilla, S. M., Sarrió, D., Honrado, E., Hardisson, D., Calero, F., Benitez, J. and Palacios, J. (2006)
‘Prognostic signi昀椀cance of basal-like phenotype and fascin expression in node-negative invasive breast
carcinomas’, Clinical Cancer Research, 12(5), 1533-1539.
Rosenberg, L., Palmer, J. R., Rao, R. S., Zauber, A. G., Strom, B. L., Warshauer, M. E., Harlap, S. and Shapiro,
S. (1996) ‘Case-control study of oral contraceptive use and risk of breast cancer’, American Journal of
Epidemiology, 143(1).
Siegel, R., Naishadham, D. and Jemal, A. (2013) ‘Cancer statistics, 2013’, CA: A Cancer Journal for Clinicians,
63(1), 11-30.
Siegel, R. L., Miller, K. D. and Jemal, A. (2015) ‘Cancer statistics, 2015’, CA: A Cancer Journal for Clinicians,
65(1), 5-29.
Siegel, R. L., Miller, K. D. and Jemal, A. (2016) ‘Cancer statistics, 2016’, CA: A Cancer Journal for Clinicians,
66(1), 7-30.
Sirohi, B., Arnedos, M., Popat, S., Ashley, S., Nerurkar, A., Walsh, G., Johnston, S. and Smith, I. (2008)
‘Platinum-based chemotherapy in triple-negative breast cancer’, Annals of Oncology, 19(11), 1847-1852.
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M.
and Jeffrey, S. S. (2001) ‘Gene expression patterns of breast carcinomas distinguish tumor subclasses with
clinical implications’, Proceedings of the National Academy of Sciences, 98(19), 10869-10874.
Uematsu, T., Kasami, M. and Yuen, S. (2009) ‘Triple-Negative Breast Cancer: Correlation between MR Imaging
and Pathologic Findings 1’, Radiology, 250(3), 638-647.
Uscanga-Perales, G. I., Santuario-Facio, S. K. and Ortiz-López, R. (2016) ‘Triple negative breast cancer:
Deciphering the biology and heterogeneity’, Medicina Universitaria, 18(71), 105-114.
von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann,
W., Hilfrich, J. and Huober, J. (2012) ‘De昀椀nition and impact of pathologic complete response on prognosis after
neoadjuvant chemotherapy in various intrinsic breast cancer subtypes’, Journal of Clinical Oncology, 30(15),
1796-1804.
Wilson, J. D., Grif昀椀n, J. E., Leshin, M. and George, F. W. (1981) ‘Role of gonadal hormones in development of
the sexual phenotypes’, Human Genetics, 58(1), 78-84.
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C.,
Bartlett, J. M., Bilous, M. and Fitzgibbons, P. (2013) ‘Recommendations for human epidermal growth factor
receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists
clinical practice guideline update’, Journal of Clinical Oncology, 31(31), 3997-4013.
Zheng, Y.-X., Yang, M., Rong, T.-T., Yuan, X.-L., Ma, Y.-H., Wang, Z.-H., Shen, L.-S. and Cui, L. (2012) ‘CD74
and macrophage migration inhibitory factor as therapeutic targets in gastric cancer’, World Journal of
Gastroenterology: WJG, 18(18), 2253.
Zhu, K., Bernard, L., Levine, R. and Williams, S. (1997) ‘Estrogen receptor status of breast cancer: a marker of
different stages of tumor or different entities of the disease?’, Medical Hypotheses, 49(1), 69-75.
54
SOCRA SOURCE © May 2024